Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.25

-0.4%

Dec 12 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (65)	8/3/1998 3:29:00 PM
From: Mike McFarland	Read Replies (1) of 1475

off topic For psoriasis and other autoimmune diseases, the effective (IMO) competition will be CTLA4 from Bristol-Myers Squibb, Zenapax from PDLI/Roche, and anti-CD40L from Idec and/or Biogen. Haven't seen you on the Repligen thread, any thoughts about the CTLA4 complaint? Like my Ligand warrants, I repurchased RGEN today. But this market has been really tough, I took a beating in Arqule and got stopped out--twice. The only other biotech I own is Targeted Genetics--I put my wife into that one and it immediately went down 20%.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next